Immodulon is an independent biopharmaceutical company pioneering gentle immunotherapy treatments, in particular for cancer.
Immunotherapy is now recognised as the biggest breakthrough since chemotherapy in the treatment of cancer. Immodulon’s research demonstrates that its lead product is potentially transformational in improving the overal outcome for patients by use in combination with other anti-cancer treatments.
IMM‑101 is a naturally derived medical treatment that helps the body’s immune system to recognise and control cancer. It works in combination with other anti-cancer treatments to improve the overall outcome for patients. Clinical studies indicate that IMM‑101 has a potentially transformational impact on survival rates for cancer.
Immodulon is a small, independent biopharmaceutical company that has attracted significant investment to date, predominately from High Net Worth Individuals and impact investors.
Latest News & Research
News19 May 2017Laura Rosa Brunet, Immodulon’s Chief Scientific Officer, published in Journal for ImmunoTherapy of CancerRead more
News15 May 2017Labiotech interview with Immodulon’s CEO, Linda SummertonRead more
Events03 May 2017Immodulon CEO speaks at Europe’s leading biopartnering and investment conferenceRead more
News03 May 2017Immodulon CEO, Linda Summerton, shortlisted for First Women Awards 2017Read more
News02 May 2017Grant awarded to Professor Stefan Reber for work involving IMM-201Read more